Analyst Reco. Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Real-time Estimate Cboe BZX Other stock markets 01:46:59 2024-05-24 pm EDT			5-day change	1st Jan Change
392.6 ^USD	+0.52%		-0.08%	+28.21%

May. 22	Medpace Holdings Insider Sold Shares Worth $1,608,764, According to a Recent SEC Filing	MT
May. 17	Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medpace Holdings Insider Sold Shares Worth $1,608,764, According to a Recent SEC Filing	May. 22	MT
Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing	May. 17	MT
Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing	May. 14	MT
Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing	May. 08	MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing	May. 03	MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing	May. 01	MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating	Apr. 24	MT
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450	Apr. 23	MT
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target	Mar. 18	MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating	Mar. 08	MT
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282	Feb. 15	MT
UBS Adjusts Medpace Price Target to $282 From $270, Maintains Neutral Rating	23-10-25	MT
Baird Upgrades Medpace Holdings to Outperform From Neutral, Adjusts Price Target to $289 From $270	23-10-24	MT
UBS Adjusts Medpace Price Target to $270 From $215, Maintains Neutral Rating	23-07-26	MT
Guggenheim Raises Medpace Holdings' Price Target to $273 From $252, Keeps Buy Rating	23-07-25	MT
Guggenheim Upgrades Medpace Holdings to Buy From Neutral, Price Target is $252	23-05-08	MT
UBS Lowers Price Target on Medpace to $215 From $238, Keeps Neutral Rating	23-04-10	MT
UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $238 From $142	22-10-27	MT
Baird Adjusts Medpace Holdings' Price Target to $217 From $200, Keeps Neutral Rating	22-10-26	MT
Baird Adjusts Price Target on Medpace Holdings to $200 From $145, Maintains Neutral Rating	22-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Medpace Holdings, Inc: A winning stock that went under the radar

June 29, 2022 at 10:45 am EDT